SEARCH

SEARCH BY CITATION

References

  • Chapin, J., Wekslezr, B., Magro, C. & Laurence, J. (2012) Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. British Journal of Haematology, 157, 772774.
  • Furlan, M., Robles, R., Galbusera, M., Remuzzi, G., Kyrle, P.A., Brenner, B., Krause, M., Scharrer, I., Aumann, V., Mittler, U., Solenthaler, M. & Lammle, B. (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome [see comments]. The New England Journal of Medicine, 339, 15781584.
  • Kavanagh, D. & Goodship, T.H. (2010) Atypical hemolytic uremic syndrome. Current Opinion in Hematology, 17, 432438.
  • Noris, M., Ruggenenti, P., Perna, A., Orisio, S., Caprioli, J., Skerka, C., Vasile, B., Zipfel, P.F. & Remuzzi, G. (1999) Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. Journal of American Society of Nephrology, 10, 281293.
  • Noris, M., Bucchioni, S., Galbusera, M., Donadelli, R., Bresin, E., Castelletti, F., Caprioli, J., Brioschi, S., Scheiflinger, F. & Remuzzi, G. (2005) Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. Journal of American Society of Nephrology, 16, 11771183.
  • Reti, M., Farkas, P., Csuka, D., Razso, K., Schlammadinger, A., Udvardy, M.L., Madach, K., Domjan, G., Bereczki, C., Reusz, G.S., Szabo, A.J. & Prohaszka, Z. (2012) Complement activation in thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 10, 791798.
  • Ruiz-Torres, M.P., Casiraghi, F., Galbusera, M., Macconi, D., Gastoldi, S., Todeschini, M., Porrati, F., Belotti, D., Pogliani, E.M., Noris, M. & Remuzzi, G. (2005) Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Journal of Thrombosis and Haemostasis, 93, 443452.
  • Sanchez-Corral, P., Gonzalez-Rubio, C., Rodriguez de, C.S. & Lopez-Trascasa, M. (2004) Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Molecular Immunology, 41, 8184.
  • Stahl, A.L., Vaziri-Sani, F., Heinen, S., Kristoffersson, A.C., Gydell, K.H., Raafat, R., Gutierrez, A., Beringer, O., Zipfel, P.F. & Karpman, D. (2008) Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood, 111, 53075315.
  • Tsai, H.M. (2006) The molecular biology of thrombotic microangiopathy. Kidney International, 70, 1623.